First Insurance Coverage in Japan for JAK2V617F Gene Mutation Testing for Myeloproliferative Neoplasms.
Sysmex Corporation (HQ: Kobe, Japan; Chairman & CEO: Hisashi Ietsugu) announces its launch of the ipsogen JAK2 DX reagent. The company received marketing approval on the reagent on December 19, 2018. This product is a gene testing kit that measures the JAK2V617F mutation1 quantitatively, used in the diagnosis of certain hematopoietic tumors generally referred to as blood cancers, specifically polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) will present two posters showing the most recent data on using blood as a method of diagnosing Alzheimer’s disease at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference, which is scheduled to take place from December 4 to 7, 2019 in San Diego, California, United States. Sysmex is conducting this development in collaboration with Eisai Co., Ltd. (HQ: Tokyo, Japan; CEO: Haruo Naito).
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received a Minister of Education, Culture, Sports, Science and Technology Prize, and Encouragement Prizes for Inventions, at the Kinki* Local Commendation for Inventions, sponsored by the Japan Institute of Invention and Innovation.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and OPTiM Corporation (HQ: Minato-ku, Tokyo, Japan; President: Shunji Sugaya) have announced a basic agreement to establish a joint venture for the planning, development, and operation of solution services utilising platforms and applications related to digital medicine, with the aim of accelerating the commercialisation of digital medicine.
Kobe University (Location: Kobe, Japan; President: Hiroshi Takeda), the city of Kobe (Location: Kobe, Japan; Mayor: Kizo Hisamoto), the Foundation for Biomedical Research and Innovation at Kobe (Location: Kobe, Japan; President: Tasuku Honjo) and Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announce the establishment of the BioResource Innovation Hub in Kobe (Location: Kobe, Japan; Representative Director: Kenji Tsujimoto; “BRIH-K”) as a general incorporated association formed through an industry–government–academia alliance.
Sysmex Corporation (HQ: Kobe, Japan; Chairman & CEO: Hisashi Ietsugu) and Kyoto University (Sakyo-ku, Kyoto, Japan; President: Juichi Yamagiwa) announce the development of a fully automated measurement method for soluble immune checkpoint molecules (sPD-1, sPD-L1 and sCTLA-4) through joint R&D conducted since 2013 by Sysmex and Tasuku Honjo, a distinguished professor at the Kyoto University Institute for Advanced Studies. The two parties will proactively conduct clinical research using this measurement method to create new diagnostic technologies for cancer and immune disease.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the fourth consecutive year.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that the CC-1001 automated hematology analyzer, which the Company developed as Japan’s first instrument for automatically measuring the number of red and white blood cells, has been registered by Japan’s National Museum of Nature and Science (Director General: Yoshihiro Hayashi) as “Essential Historical Material for Science and Technology”, also known colloquially as “MIRAI Technology Heritage.”
Sysmex Corporation (HQ: Kobe, Japan; Chairman & CEO: Hisashi Ietsugu) announces the launch of its PS-10 sample preparation system in the North American market from August 2019. By automating complicated sample preparation work for clinical laboratories, the PS-10 results in providing workflows which are more efficient and aids in standardizing clinical flow cytometry testing. Sysmex will move product development and assessment of the clinical utility with flow cytometry as analyzers forward, aiming for a global rollout of the entire clinical flow cytometry system including the PS-10.
Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has obtained Japanese manufacturing and marketing approval for the OncoBEAM™1 RAS CRC Kit, used for blood-based circulating tumor DNA molecular testing of mutations in the RAS gene2 for colorectal cancer patients. This product is the first in vitro diagnostic reagent in Japan to be used for RAS gene mutation testing for colorectal cancer using liquid biopsy. Minimally invasive and simpler than conventional physical biopsies of tumor tissue, the new testing method provides detection results on a par with the use of tumor tissue.3 As a result, this testing method reduces the physical and mental burden on patients, expands testing opportunities, and contributes to the early-stage determination of treatment methods.